Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Core Insights - Spyre Therapeutics announced positive interim Phase 1 results for SPY002 and SPY072, two novel monoclonal antibodies targeting TL1A, indicating their potential as next-generation therapies for immune-mediated diseases [1][2][3] Clinical Trials and Results - SPY002 and SPY072 met all Phase 1 objectives, demonstrating safety and tolerability with single doses up to 1500 mg, and a prolonged half-life of approximately 75 days, which is over three times greater than first-generation anti-TL1A antibodies [2][9] - The SKYLINE-UC platform trial for ulcerative colitis was initiated in May 2025, evaluating optimized monotherapies and combinations [1][3] - The SKYWAY-RD basket trial for SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis is expected to begin in Q3 2025 [1][4] Future Development Plans - The company plans to advance SPY002 into the SKYLINE-UC trial and initiate the SKYWAY-RD trial for SPY072, with expectations for multiple proof-of-concept data readouts in 2026 and 2027 [3][5][7] - The SKYLINE-UC trial will include SPY001, SPY002, SPY003, and their combinations under a single master protocol [3][8] Market Potential - The company is well-funded with a cash runway extending into the second half of 2028, aiming to deliver nine proof-of-concept readouts in markets exceeding $60 billion in annual revenue [7][14]